New Risk • Jun 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (9.8% average weekly change). Reported Earnings • May 31
Full year 2026 earnings released: ₹0.88 loss per share (vs ₹1.37 loss in FY 2025) Full year 2026 results: ₹0.88 loss per share (improved from ₹1.37 loss in FY 2025). Revenue: ₹6.57b (up 18% from FY 2025). Net loss: ₹53.7m (loss narrowed 36% from FY 2025). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 51% per year, which means it is well ahead of earnings. Announcement • May 23
Panacea Biotec Limited to Report Q4, 2026 Results on May 29, 2026 Panacea Biotec Limited announced that they will report Q4, 2026 results on May 29, 2026 Reported Earnings • Feb 12
Third quarter 2026 earnings released: EPS: ₹0.65 (vs ₹0.74 in 3Q 2025) Third quarter 2026 results: EPS: ₹0.65 (down from ₹0.74 in 3Q 2025). Revenue: ₹1.67b (up 2.4% from 3Q 2025). Net income: ₹39.8m (down 12% from 3Q 2025). Profit margin: 2.4% (down from 2.8% in 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 193 percentage points per year, which is a significant difference in performance. Announcement • Feb 02
Panacea Biotec Limited to Report Q3, 2026 Results on Feb 11, 2026 Panacea Biotec Limited announced that they will report Q3, 2026 results on Feb 11, 2026 New Risk • Dec 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.4% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change). Reported Earnings • Nov 16
Second quarter 2026 earnings released: ₹2.27 loss per share (vs ₹0.77 profit in 2Q 2025) Second quarter 2026 results: ₹2.27 loss per share (down from ₹0.77 profit in 2Q 2025). Revenue: ₹1.48b (flat on 2Q 2025). Net loss: ₹139.2m (down 390% from profit in 2Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 190 percentage points per year, which is a significant difference in performance. Announcement • Nov 04
Panacea Biotec Limited to Report Q2, 2026 Results on Nov 14, 2025 Panacea Biotec Limited announced that they will report Q2, 2026 results on Nov 14, 2025 Announcement • Aug 18
Panacea Biotec Limited, Annual General Meeting, Sep 30, 2025 Panacea Biotec Limited, Annual General Meeting, Sep 30, 2025, at 11:30 Indian Standard Time. Reported Earnings • Aug 16
First quarter 2026 earnings released: EPS: ₹0.66 (vs ₹2.59 loss in 1Q 2025) First quarter 2026 results: EPS: ₹0.66 (up from ₹2.59 loss in 1Q 2025). Revenue: ₹1.72b (up 49% from 1Q 2025). Net income: ₹40.5m (up ₹198.5m from 1Q 2025). Profit margin: 2.3% (up from net loss in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 182 percentage points per year, which is a significant difference in performance. Announcement • Aug 04
Panacea Biotec Limited to Report Q1, 2026 Results on Aug 14, 2025 Panacea Biotec Limited announced that they will report Q1, 2026 results on Aug 14, 2025 New Risk • Jul 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Jun 02
Full year 2025 earnings released: ₹1.37 loss per share (vs ₹0.19 loss in FY 2024) Full year 2025 results: ₹1.37 loss per share (further deteriorated from ₹0.19 loss in FY 2024). Revenue: ₹5.59b (flat on FY 2024). Net loss: ₹83.7m (loss widened ₹72.0m from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 177 percentage points per year, which is a significant difference in performance. Announcement • May 24
Panacea Biotec Limited to Report Q4, 2025 Results on May 30, 2025 Panacea Biotec Limited announced that they will report Q4, 2025 results on May 30, 2025 Board Change • Apr 02
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Non-Executive Independent Director Ambika Sharma was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Apr 01
Panacea Biotec Limited Announces Cessation of Narotam Kumar Juneja as Director and Chairperson / Member of the Committees of the Board of Directors, Effective March 31, 2025 Panacea Biotec Limited announced that Narotam Kumar Juneja (DIN: 01204817), non-executive non-independent director of the Company was re-appointed as director liable to retire by rotation, in the Annual General Meeting ("AGM") held on September 27, 2024, for a period upto March 31, 2025. Accordingly, he has completed his tenure as non-executive non-independent director and consequently ceased to be the director of the Company on March 31, 2025. Accordingly, he has also ceased to be the Chairperson /member of the Committees of the Board of Directors of the Company. Similarly, Mr. Narotam Kumar Juneja has also completed his tenure as Whole-time Director in the Company's material subsidiary viz., Panacea Biotec Pharma Limited ("PBPL") and consequently ceased to be the director of PBPL on March 31, 2025. Announcement • Mar 31
Panacea Biotec Limited Announces Cessation of Manjula Upadhyay as Independent Director, Chairperson/Member of the Committees of the Board of Director Panacea Biotec Limited informed that Mrs. Manjula Upadhyay, Independent Director of the Company has completed her second and final term of five consecutive years as Independent Director on March 29, 2025 and consequently she has ceased to be the director of the Company. Accordingly, she has also ceased to be the Chairperson /member of the Committees of the Board of Directors of the Company. Mrs. Manjula Upadhyay will however continue to be non-executive independent director of the Company's material wholly-owned subsidiary company, Panacea Biotec Pharma Limited. Reported Earnings • Feb 15
Third quarter 2025 earnings released: EPS: ₹0.74 (vs ₹0.37 loss in 3Q 2024) Third quarter 2025 results: EPS: ₹0.74 (up from ₹0.37 loss in 3Q 2024). Revenue: ₹1.67b (up 11% from 3Q 2024). Net income: ₹45.2m (up ₹67.2m from 3Q 2024). Profit margin: 2.7% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 103 percentage points per year, which is a significant difference in performance. Announcement • Jan 31
Panacea Biotec Limited to Report Q3, 2025 Results on Feb 14, 2025 Panacea Biotec Limited announced that they will report Q3, 2025 results on Feb 14, 2025 Recent Insider Transactions • Jan 01
Joint MD & Executive Director recently sold ₹6.5m worth of stock On the 24th of December, Sandeep Jain sold around 15k shares on-market at roughly ₹435 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹29m. Sandeep has been a net seller over the last 12 months, reducing personal holdings by ₹189m. Recent Insider Transactions • Dec 14
Joint MD & Executive Director recently sold ₹7.0m worth of stock On the 11th of December, Sandeep Jain sold around 16k shares on-market at roughly ₹454 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹29m. Sandeep has been a net seller over the last 12 months, reducing personal holdings by ₹174m. Recent Insider Transactions • Dec 03
Joint MD & Executive Director recently sold ₹9.5m worth of stock On the 29th of November, Sandeep Jain sold around 23k shares on-market at roughly ₹421 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹33m. Sandeep has been a net seller over the last 12 months, reducing personal holdings by ₹163m. Recent Insider Transactions • Nov 24
Joint MD & Executive Director recently sold ₹29m worth of stock On the 21st of November, Sandeep Jain sold around 74k shares on-market at roughly ₹391 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹33m. Sandeep has been a net seller over the last 12 months, reducing personal holdings by ₹149m. Reported Earnings • Nov 15
Second quarter 2025 earnings released: EPS: ₹0.77 (vs ₹1.35 loss in 2Q 2024) Second quarter 2025 results: EPS: ₹0.77 (up from ₹1.35 loss in 2Q 2024). Revenue: ₹1.52b (up 6.3% from 2Q 2024). Net income: ₹48.0m (up ₹130.9m from 2Q 2024). Profit margin: 3.2% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings. Announcement • Oct 30
Panacea Biotec Limited to Report Q2, 2025 Results on Nov 13, 2024 Panacea Biotec Limited announced that they will report Q2, 2025 results on Nov 13, 2024 Announcement • Oct 18
Panacea Biotec Limited Announces Demise of Bhupinder Singh, Independent Director, Member of the Board and Committee Panacea Biotec Limited announced that the sad demise of Mr. Bhupinder Singh, Independent Director of the Company on October 16, 2024. Mr. Bhupinder Singh was Independent Director of the Company since April 08, 2019. During his tenure as Director on the Board, the Company has immensely benefited from his thorough knowledge and rich experience as a member of the Board and Committee thereof. The Directors and Employees of the Company convey their deep sympathy and condolences to his family. Recent Insider Transactions • Aug 23
Joint MD & Executive Director recently sold ₹1.3m worth of stock On the 20th of August, Sandeep Jain sold around 7k shares on-market at roughly ₹181 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹7.4m. Sandeep has been a net seller over the last 12 months, reducing personal holdings by ₹15m. New Risk • Aug 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Significant insider selling over the past 3 months (₹14m sold). Reported Earnings • Aug 15
First quarter 2025 earnings released: ₹2.59 loss per share (vs ₹1.79 profit in 1Q 2024) First quarter 2025 results: ₹2.59 loss per share (down from ₹1.79 profit in 1Q 2024). Revenue: ₹1.20b (down 7.5% from 1Q 2024). Net loss: ₹158.0m (down 244% from profit in 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 20% per year. Announcement • Aug 14
Panacea Biotec Limited, Annual General Meeting, Sep 27, 2024 Panacea Biotec Limited, Annual General Meeting, Sep 27, 2024, at 11:30 Indian Standard Time. Announcement • Aug 02
Panacea Biotec Limited to Report Q1, 2025 Results on Aug 14, 2024 Panacea Biotec Limited announced that they will report Q1, 2025 results on Aug 14, 2024 Recent Insider Transactions • Jun 22
Joint MD & Executive Director recently sold ₹1.3m worth of stock On the 19th of June, Sandeep Jain sold around 10k shares on-market at roughly ₹133 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Sandeep's only on-market trade for the last 12 months. Reported Earnings • Jun 04
Full year 2024 earnings released: ₹0.19 loss per share (vs ₹5.43 loss in FY 2023) Full year 2024 results: ₹0.19 loss per share (improved from ₹5.43 loss in FY 2023). Revenue: ₹5.85b (up 27% from FY 2023). Net loss: ₹11.7m (loss narrowed 97% from FY 2023). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. New Risk • May 09
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹8.15b (US$97.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. New Risk • Mar 13
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹8.28b (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Reported Earnings • Feb 15
Third quarter 2024 earnings released: ₹0.37 loss per share (vs ₹3.16 profit in 3Q 2023) Third quarter 2024 results: ₹0.37 loss per share (down from ₹3.16 profit in 3Q 2023). Revenue: ₹1.51b (up 31% from 3Q 2023). Net loss: ₹22.0m (down 111% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Announcement • Jan 31
Panacea Biotec Limited to Report Q3, 2024 Results on Feb 13, 2024 Panacea Biotec Limited announced that they will report Q3, 2024 results on Feb 13, 2024 Announcement • Dec 14
Panacea Biotec Launches EasyFourPol® in India and Receives Registration of Valganciclovir Powder for Oral Solution in Germany Panacea Biotec Limited announced the launch of world's first fully-liquid wP-IPV based Pentavalent vaccine, EasyFourPol®, in India and registration of Valganciclovir 50 mg/ml Powder for Oral Solution by its step down wholly-owned subsidiary company, Panacea Biotec Germany GmbH, in Germany. EasyFourPol® is the world's first fully liquid wP-IPV Pentavalent vaccine. wP-IPV Pentavalent vaccine protects children against five deadly diseases i.e. Diphtheria, Tetanus, Pertussis, Polio, and invasive infections caused by Haemophilus Influenza Type b. Valganciclovir 50 mg/ml Powder for Oral Solution competes in a 1 million market (as per IQVIA). The medication is a deoxynucleoside analogue cytomegalovirus DNA polymerase inhibitor indicated for: the initial and maintenance treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS). the prophylaxis of CMV disease in CMV-negative adults and children (from birth and up to 18 years of age) who have received an organ transplant from a CMV-positive donor. Reported Earnings • Nov 12
Second quarter 2024 earnings released: ₹1.35 loss per share (vs ₹2.56 profit in 2Q 2023) Second quarter 2024 results: ₹1.35 loss per share (down from ₹2.56 profit in 2Q 2023). Revenue: ₹1.46b (up 39% from 2Q 2023). Net loss: ₹82.9m (down 153% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • Oct 24
Panacea Biotec Limited to Report Q2, 2024 Results on Nov 10, 2023 Panacea Biotec Limited announced that they will report Q2, 2024 results on Nov 10, 2023 New Risk • Oct 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.0% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.0% net profit margin). Valuation Update With 7 Day Price Move • Sep 18
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹165, the stock trades at a trailing P/E ratio of 30.3x. Average trailing P/E is 30x in the Biotechs industry in India. Total loss to shareholders of 16% over the past three years. New Risk • Aug 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.0% net profit margin). Valuation Update With 7 Day Price Move • Aug 22
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹158, the stock trades at a trailing P/E ratio of 29.1x. Average trailing P/E is 35x in the Biotechs industry in India. Total loss to shareholders of 17% over the past three years. Reported Earnings • Aug 13
First quarter 2024 earnings released: EPS: ₹1.79 (vs ₹9.17 loss in 1Q 2023) First quarter 2024 results: EPS: ₹1.79 (up from ₹9.17 loss in 1Q 2023). Revenue: ₹1.29b (up 17% from 1Q 2023). Net income: ₹109.8m (up ₹671.2m from 1Q 2023). Profit margin: 8.5% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Announcement • Jul 30
Panacea Biotec Limited to Report Q1, 2024 Results on Aug 12, 2023 Panacea Biotec Limited announced that they will report Q1, 2024 results at 12:08 PM, Indian Standard Time on Aug 12, 2023 Reported Earnings • May 31
Full year 2023 earnings released: ₹5.51 loss per share (vs ₹176 profit in FY 2022) Full year 2023 results: ₹5.51 loss per share (down from ₹176 profit in FY 2022). Revenue: ₹5.12b (down 23% from FY 2022). Net loss: ₹337.5m (down 103% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 15
Third quarter 2023 earnings released: EPS: ₹3.16 (vs ₹8.03 loss in 3Q 2022) Third quarter 2023 results: EPS: ₹3.16 (up from ₹8.03 loss in 3Q 2022). Revenue: ₹1.15b (down 26% from 3Q 2022). Net income: ₹193.7m (up ₹685.7m from 3Q 2022). Profit margin: 17% (up from net loss in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 19
Second quarter 2023 earnings released: EPS: ₹2.56 (vs ₹8.65 loss in 2Q 2022) Second quarter 2023 results: EPS: ₹2.56 (up from ₹8.65 loss in 2Q 2022). Revenue: ₹1.05b (down 55% from 2Q 2022). Net income: ₹157.0m (up ₹687.1m from 2Q 2022). Profit margin: 15% (up from net loss in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 5 highly experienced directors. Additional Non-Executive Non-Independent Director Narotam Juneja was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Oct 09
Panacea Biotec Limited Announces Demise of Shri Soshil Kumar Jain, the Founder, Chairman Panacea Biotec Limited announced that Shri Soshil Kumar Jain, the Founder, Chairman and the patriarch of Promoters family of the company has left for his heavenly abode on October 07, 2022. Shri Soshil Kumar Jain's sudden and unexpected passing away will be an irreparable loss to the Company and all the directors and employees of the Company convey deep sympathy, son-ow and condolences to his bereaved family members. Reported Earnings • Aug 10
First quarter 2023 earnings released: ₹9.17 loss per share (vs ₹9.36 loss in 1Q 2022) First quarter 2023 results: ₹9.17 loss per share (up from ₹9.36 loss in 1Q 2022). Revenue: ₹1.23b (down 7.2% from 1Q 2022). Net loss: ₹561.4m (loss narrowed 2.1% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Announcement • Aug 10
Panacea Biotec Limited, Annual General Meeting, Sep 28, 2022 Panacea Biotec Limited, Annual General Meeting, Sep 28, 2022, at 11:30 Indian Standard Time. Announcement • Jul 28
Panacea Biotec Limited to Report Q1, 2023 Results on Aug 09, 2022 Panacea Biotec Limited announced that they will report Q1, 2023 results on Aug 09, 2022 Board Change • Jun 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 6 highly experienced directors. Additional Non-Executive Non-Independent Director Narotam Juneja was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • May 22
Full year 2022 earnings released: EPS: ₹176 (vs ₹23.88 loss in FY 2021) Full year 2022 results: EPS: ₹176 (up from ₹23.88 loss in FY 2021). Revenue: ₹6.61b (up 5.8% from FY 2021). Net income: ₹10.8b (up ₹12.2b from FY 2021). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Board Change • May 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 6 highly experienced directors. Additional Non-Executive Non-Independent Director Narotam Juneja was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 03
Panacea Biotec Limited Appoints Narotam Kumar Juneja as an Additional Director Panacea Biotec Limited appointed Mr. Narotam Kumar Juneja (DIN: 01204817) as an additional director (in the capacity of Non-Executive Non-Independent Director) on the Board of Directors of the Company with effect from April 01, 2022. Board Change • Mar 13
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 6 highly experienced directors. Non Executive Independent Director Bhupinder Singh was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 16
Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint Third quarter 2022 results: ₹8.03 loss per share (down from ₹6.54 loss in 3Q 2021). Revenue: ₹1.58b (up 11% from 3Q 2021). Net loss: ₹492.0m (loss widened 23% from 3Q 2021). Revenue missed analyst estimates by 6.7%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 85 percentage points per year, which is a significant difference in performance. Reported Earnings • Jul 24
First quarter 2022 earnings released: ₹9.36 loss per share (vs ₹5.41 loss in 1Q 2021) The company reported a soft first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2022 results: Revenue: ₹1.36b (up 2.2% from 1Q 2021). Net loss: ₹573.5m (loss widened 73% from 1Q 2021). Announcement • Jul 06
Panacea Biotec Announces Receipt of Manufacturing License to Produce Sputnik V Vaccine at Baddi, Himachal Pradesh Panacea Biotec announced receipt of manufacturing license from Drugs Controller General (India) for Sputnik V vaccine against Covid-19 pursuant to its collaboration with Russian Direct Investment Fund (Russia's sovereign wealth fund). The license is a necessary condition for using Sputnik V produced by Panacea Biotec in India. The batches produced at Panacea Biotec's facilities at Baddi, Himachal Pradesh were earlier shipped to the Gamaleya Center in Russia for quality control. The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli, Himachal Pradesh in India. Sputnik V was registered in India under the emergency use authorization procedure on April 12, 2021 and vaccination against Covid-19 with the Russian vaccine started on May 14, 2021. Sputnik V has been registered in 67 countries globally with total population of over 3.5 billion people. The vaccine is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots. Reported Earnings • Jun 04
Full year 2021 earnings released: ₹23.87 loss per share (vs ₹30.67 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: ₹6.35b (up 17% from FY 2020). Net loss: ₹1.46b (loss narrowed 22% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance. Announcement • May 25
The Russian Direct Investment Fund and Panacea Biotec Announce the Launch of Production of the Russian Sputnik V Vaccine Against Coronavirus The Russian Direct Investment Fund and Panacea Biotec announced the launch of production of the Russian Sputnik V vaccine against coronavirus. The first batch produced at Panacea Biotec's facilities at Baddi will be shipped to the Gamaleya Center for quality control. Full-scale production of the vaccine is due to star this summer, Company's facilities comply with GMP standards and are prequalified by WHO. Sputnik V was registered in India under the emergency use authorization procedure on April 12, 2021 and vaccination against coronavirus with the Russian vaccine started on May 14. As announced in April, RDIF and Panacea have agreed to produce 100 million doses per year of SputnikvV. To date Sputnik V has been registered in 66 countries globally with total population of over 3.2 billion people. Efficacy of Sputnik V is 97.6% based on the analysis of data on coronavirus infection rate among those in Russia vaccinated with both components of Sputnik V from December 5, 2020 to March 31, 2021. The vaccine is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots. Is New 90 Day High Low • Mar 15
New 90-day low: ₹185 The company is down 22% from a price of ₹238 on 15 December 2020. Underperformed the Indian market, which is up 14% over the last 90 days. Lagged the Biotechs industry, which is down 11% over the same period. Reported Earnings • Feb 13
Third quarter 2021 earnings released: ₹6.54 loss per share (vs ₹3.29 loss in 3Q 2020) The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: ₹1.44b (down 14% from 3Q 2020). Net loss: ₹400.5m (loss widened 99% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 68% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Announcement • Feb 03
Panacea Biotec Limited to Report Q3, 2021 Results on Feb 12, 2021 Panacea Biotec Limited announced that they will report Q3, 2021 results on Feb 12, 2021 Is New 90 Day High Low • Dec 02
New 90-day high: ₹246 The company is up 30% from its price of ₹189 on 03 September 2020. The Indian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period. Reported Earnings • Nov 12
Second quarter 2021 earnings released: ₹3.09 loss per share The company reported a solid second quarter result with reduced losses and improved revenues and control over expenses. Second quarter 2021 results: Revenue: ₹1.84b (up 47% from 2Q 2020). Net loss: ₹189.0m (loss narrowed 74% from 2Q 2020). Announcement • Nov 12
Panacea Biotec Limited, Annual General Meeting, Dec 24, 2020 Panacea Biotec Limited, Annual General Meeting, Dec 24, 2020, at 11:30 Indian Standard Time. Is New 90 Day High Low • Oct 16
New 90-day low: ₹181 The company is down 8.0% from its price of ₹196 on 17 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period. Announcement • Oct 10
Panacea Biotec Limited Announces Resignation of Sunanda Jain and Mr. Sumit Jain, Whole-Time Directors Panacea Biotec Limited that Mrs. Sunanda Jain and Mr. Sumit Jain, Whole-time Directors of the Company, have resigned from the Board of Directors of the Company and the said resignations have become effective from 7th October, 2020. Announcement • Oct 08
Panacea Biotec Limited (BSE:531349) completed the spin-off of Radhika Heights Limited. Panacea Biotec Limited (BSE:531349) signed a memorandum of settlement to spin-off Radhika Heights Limited on August 29, 2017. Under the terms of the transaction, existing shares held by Panacea Biotec in Radhika Heights will be cancelled and Radhika Heights will issue new shares to all the shareholders of Panacea Biotec in the same proportion and the new shares of Radhika Heights will be listed on BSE and NSE. Radhika Heights will issue 2 fully paid equity shares to the equity shareholders of Panacea Biotec for every one equity share held by them in Panacea Biotec and one 0.5% cumulative non- convertible and non- participating redeemable preference share of Radhika Heights to the preference shareholders of Panacea Biotec for every 100 preference shares held by them in Panacea Biotec. Radhika Heights reported total revenues of INR 41.1 million for the financial year ended March 31, 2017. Radhika Heights Limited will be managed by Ravinder Jain. The deal is subject to approvals from the board of directors, banks, lending institutions, SEBI, NSE, BSE, shareholders, creditors and the national company law tribunal. As of February 26, 2019, the demerger has been approved by the Board of Directors of Panacea Biotec Limited. As of September 9, 2020, National Company Law Tribunal, Chandigarh Bench (“NCLT”) approved the transaction. The record date is set at September 22, 2020.
Panacea Biotec Limited (BSE:531349) completed the spin-off of Radhika Heights Limited on October 6, 2020. Shareholders will receive 1 equity share in the Resulting Company, for every 1 equity share held in the Demerged Company; and 1 0.5% cumulative non-convertible and non-participating preference share in the Resulting Company for every 100 preference shares (i.e. 0.5% cumulative non-convertible and non-participating Redeemable Preference Share) held in the Demerged Company. The new Equity Shares issued & allotted by Resulting Company to the shareholders of the Demerged Company in accordance with the Scheme shall be listed and/or admitted to trading on the BSE Limited and National Stock Exchange ofIndia Limited (NSE), subject to requisite approvals of Exchanges/SEBI. Announcement • Sep 26
Panacea Biotec Limited Announces Completion of its Phase I/II Study to Evaluate the Safety and Immunogenicity of Vaccine, DengiAll, Single-Dose Live-Attenuated Tetravalent Vaccine Panacea Biotec Limited announced the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose live-attenuated tetravalent vaccine. According to the World Health Organization, Dengue represents one of the ten biggest global health threats, and it is critical that have access to a safe and effective vaccine candidate that can reduce the devastating impact of Dengue fever in endemic regions. DengiAll has illustrated the strength of PanaceaBiotec's expertise in vaccinology, research, development, and manufacturing while leveraging NIH's ability to work on complex biological challenges to develop breakthrough technologies. PanaceaBiotec through continued support from National Institutes of Health, Technology Development Board, and other stakeholders is in a better position to increase affordable access to DengiAll to fight Dengue, a disease that has eluded mankind for generations. With more than 3.9 billion people living in Dengue endemic areas and over 390 million infections per year, DengiAll targets a global market of over $3 billion. Announcement • Aug 26
Panacea Biotec Limited to Report Q1, 2021 Results on Sep 03, 2020 Panacea Biotec Limited announced that they will report Q1, 2021 results on Sep 03, 2020 Announcement • Jun 19
Panacea Biotec Limited to Report Q4, 2020 Results on Jun 29, 2020 Panacea Biotec Limited announced that they will report Q4, 2020 results on Jun 29, 2020